Skyline Ventures, formed in 1997, is a nationally-known venture capital firm that specializes in investing in outstanding product-focused
Business Model:
Revenue: $12.6M
Employees: 51-200
Address: 525 University Ave
City: Palo Alto
State: CA
Zip: 94301
Country: US
Skyline Ventures, formed in 1997, is a nationally-known venture capital firm that specializes in investing in outstanding product-focused healthcare companies. Their areas of expertise include small molecule and protein therapeutics; medical devices; diagnostics; and technologies that facilitate drug discovery and life science research. They all have MD or PhD degrees, and hands-on operating experience in various start-up healthcare companies that later went public. As a result, they are known for the value they offer their companies, as board members and shareholders. They are also known for being fundamental, extremely patient investors. The days when momentum investing drove the public biotechnology markets are long gone, and they are glad that they are. The public markets demand data, not dreams. As a result, it is data that drives their decision process. In considering a new investment, they focus on whether there is adequate proof of principle to believe that the company&s;s products will work. In therapeutics, for example, they look closely at whether the biochemistry, animal models and any human data make it more probable than average that the product will eventually prove to have an important therapeutic benefit. The size of the potential market and the quality of the management or founding team are critical in their evaluation as well. Skyline Ventures are value and return driven, more than driven by the stage of the investment. Most often they lead or co-lead a company&s;s first or second institutional venture round, but have previously helped found companies and invested in PIPEs and leveraged buyouts. In October 2007, they completed raising Skyline V, which has $350 million in committed capital. They have approximately $800 million under management. They target investments of $15-35 million per portfolio company over the life of the company.
Contact Phone:
+16504625800
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/2012 | Collegium Pharmaceutical | Venture Round | 22.5M |
2/2007 | Targanta Therapeutics | Series C | 70M |
2/2000 | Xenoport | Series A | 15.9M |
7/2008 | Dicerna Pharmaceuticals | Series A | 8.4M |
6/2007 | ARCA biopharma | Series B | 18M |
12/1998 | Sunesis Pharmaceuticals | Series A | 8M |
12/2013 | Sutro Biopharma | Series D | 0 |
11/2009 | Calibra Medical | Venture Round | 1.4M |
7/2007 | Satiety | Series D | 30M |
10/2002 | Alteer | Venture Round | 0 |
5/2012 | Sutro Biopharma | Series C | 16.5M |
7/2018 | Sutro Biopharma | Series E | 0 |
5/2015 | SI-BONE | Growth | 21M |
8/2008 | InteKrin | Series C | 0 |
4/2003 | Roche NimbleGen | Series D | 0 |
6/2001 | Medivance | Series B | 16M |
8/2008 | Tetraphase Pharmaceuticals | Series A | 0 |
12/1999 | Sunesis Pharmaceuticals | Series B | 25.2M |
10/2006 | Tolerx | Series D | 61M |
9/2007 | Sequel Pharmaceuticals | Series A | 20M |
5/2006 | Eledon Pharmaceuticals | Series B | 35M |
3/2006 | Proteon Therapeutics | Series A | 19M |
4/2007 | NovaCardia | Series B | 18M |
1/2013 | Crescendo Bioscience | Series D | 28M |
10/2008 | MAKO Surgical | Post-IPO Equity | 60M |
11/2010 | Sutro Biopharma | Series C | 36.5M |
3/2005 | Tolerx | Series D | 31M |
2/2009 | SpinalMotion | Venture Round | 500k |
10/2001 | Roche NimbleGen | Series B | 10.5M |
11/2006 | Tetraphase Pharmaceuticals | Series A | 10M |
3/2005 | Sirtris Pharmaceuticals | Series B | 27M |
4/2006 | Sirtris Pharmaceuticals | Series C | 37M |
9/2009 | Tetraphase Pharmaceuticals | Series B | 0 |
8/2008 | Calibra Medical | Series B | 35M |
1/2002 | Renovis | Series B | 0 |
7/2007 | Medivance | Series D | 23M |
12/2003 | KAI Pharmaceuticals | Series A | 17M |
1/2006 | MAP Pharmaceuticals | Series C | 25.2M |
9/2004 | MAP Pharmaceuticals | Series B | 30M |
3/2017 | Dicerna Pharmaceuticals | Post-IPO Debt | 0 |
11/2009 | Calypso Medical | Series E | 50M |
3/2007 | MAP Pharmaceuticals | Series D | 50M |
5/2006 | KAI Pharmaceuticals | Series B | 35M |
11/2005 | Guava Technologies | Venture Round | 7M |
6/2001 | Guava Technologies | Series B | 17.5M |
11/2003 | Applied Genetics Technologies Corporation | Venture Round | 27M |
5/2006 | Avidia | Series C | 43.8M |
6/2016 | SI-BONE | Venture Round | 26M |
4/2005 | Receptor Biologix | Series A | 33.6M |
3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
12/2009 | Genocea Biosciences | Series B | 25.7M |
7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
10/2012 | Genocea Biosciences | Series C | 30M |
12/2004 | Sirtris Pharmaceuticals | Series A | 13M |
5/2002 | Advion Inc. | Series B | 15M |
1/2011 | Genocea Biosciences | Series B | 35M |
7/2006 | Concert Pharmaceuticals | Series A | 10M |
4/2008 | Concert Pharmaceuticals | Series C | 0 |
5/2009 | Proteon Therapeutics | Series B | 50M |
3/2000 | iScribe | Series B | 21M |
6/2010 | Tetraphase Pharmaceuticals | Series C | 0 |
5/2014 | Proteon Therapeutics | Series D | 0 |
8/2010 | SI-BONE | Series B | 10.6M |
8/2005 | iBalance Medical | Series A | 8.2M |
9/2011 | SI-BONE | Venture Round | 16M |
11/2021 | Muse Technology | Series A | 0 |
11/2005 | Hansen Medical | Venture Round | - |
5/2008 | Novasys Health | Venture Round | 49.5M |
8/2011 | Proteon Therapeutics | Series C | 15.2M |
5/2008 | Novasys Medical, Inc. | Series D | 49.5M |
9/2006 | NovaCardia | Series B | 48M |
9/2007 | Proteon Therapeutics | Series A | 12M |
10/2001 | Tolerx | Series B | 17M |
4/2014 | SI-BONE | Venture Round | 33M |
11/2006 | Concert Pharmaceuticals | Series B | 48.5M |
11/2021 | Muse Technology | Series A | 0 |
7/2018 | Sutro Biopharma | Series E | 0 |
3/2017 | Dicerna Pharmaceuticals | Post-IPO Debt | 0 |
6/2016 | SI-BONE | Venture Round | 0 |
5/2015 | SI-BONE | Venture Round | 0 |
3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
5/2014 | Proteon Therapeutics | Series D | 0 |
4/2014 | SI-BONE | Venture Round | 0 |
12/2013 | Sutro Biopharma | Series D | 0 |
7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|